Sir James Black Centre, University of Dundee, UK.
Drug Discov Today. 2009 Dec;14(23-24):1150-8. doi: 10.1016/j.drudis.2009.09.004. Epub 2009 Sep 28.
The liaison between academia and the pharmaceutical industry was originally served primarily through the scientific literature and limited, specific industry-academia partnerships. Some of these partnerships have resulted in drugs on the market, such as Vorinostat (Memorial Sloan-Kettering Cancer Centre and Merck) and Tenofovir (University of Leuven; Institute of Organic Chemistry and Biochemistry, Czech Republic; and GlaxoSmithKline), but the timescales from concept to clinic have, in most cases, taken many decades. We now find ourselves in a world in which the edges between these sectors are more blurred and the establishment and acceptance of high-throughput screening alongside the wider concept of 'hit discovery' in academia provides one of the key platforms required to enable this sector to contribute directly to addressing unmet medical need.
学术界和制药业之间的联系最初主要通过科学文献和有限的、特定的产学合作来实现。这些合作中的一些已经促成了市场上的药物，如伏立诺他（纪念斯隆-凯特琳癌症中心和默克）和替诺福韦（鲁汶大学；捷克共和国有机化学与生物化学研究所；和葛兰素史克），但从概念到临床的时间尺度在大多数情况下都需要几十年。我们现在所处的世界，这些领域之间的界限更加模糊，学术界建立和接受高通量筛选以及更广泛的“命中发现”概念，为使该领域能够直接有助于解决未满足的医疗需求提供了关键平台之一。
